Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daylight PDT for Actinic Keratoses in the Northeast US
NCT02867722Withdrawn
- Sponsor
- Brigham and Women's Hospital
- Start
- Dec 2020
- Primary completion
- Dec 2021
- Modality
- Small Molecules
01
Overview
Open-label, single-arm trial of aminolevulinic acid in actinic keratosis (AK), sponsored by Brigham and Women's Hospital. Primary endpoint: Number of patients with reduction in the number of actinic keratoses at 5 years. Planned start Dec 2020; status: withdrawn.
02
Drugs
aminolevulinic acid
03
Conditions
actinic keratosis (AK)
Beyond the preview
Go deeper on NCT02867722.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02867722.